5,7-diaminopyrazolo [4,3-d] pyrimidines with PDE-5 inhibiting activity

Details for Australian Patent Application No. 2004290643 (hide)

Owner Pfizer Inc.

Inventors Dack, Kevin Neil; Morrell, Andrew Ian; Winslow, Carol Ann; Fox, David Nathan Abraham; Brown, David Graham; Bell, Andrew Simon; Marsh, Ian Roger; Palmer, Michael John

Agent Spruson & Ferguson

Pub. Number AU-B-2004290643

PCT Pub. Number WO2005/049616

Priority 0327319.0 24.11.03 GB

Filing date 12 November 2004

Wipo publication date 2 June 2005

Acceptance publication date 7 August 2008

International Classifications

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

Event Publications

25 May 2006 PCT application entered the National Phase

  PCT publication WO2005/049616 Priority application(s): WO2005/049616

27 July 2006 Amendment Made

  The nature of the amendment is: Amend the invention title to read 5,7-diaminopyrazolo [4,3-d] pyrimidines with PDE-5 inhibiting activity

7 August 2008 Application Accepted

  Published as AU-B-2004290643

4 December 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004290653-A rotational moulding process and particulate chemical composition

2004290626-Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1)